Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer

Sun Young Kong; Mi Hwa Han; Heon Jong Yoo; Jong Ha Hwang; Myong Cheol Lim; Sang Soo Seo; Chong Woo Yoo; Jae Hoon Kim; Sang Yoon Park; Sokbom Kang

doi:10.1245/s10434-011-1943-5

Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer

Sun Young Kong, Mi Hwa Han, Heon Jong Yoo, Jong Ha Hwang, Myong Cheol Lim, Sang Soo Seo, Chong Woo Yoo, Jae Hoon Kim, Sang Yoon Park, Sokbom Kang

Department of Obstetrics and Gynecology

Research output: Contribution to journal › Article › peer-review

39 Citations (Scopus)

Abstract

Background. This study was designed to determine whether serum HE4 is an independent prognostic factor in ovarian cancer patients. Methods. We measured HE4 in pretreatment serum samples from 80 women with epithelial ovarian cancer, using an enzyme-linked immunosorbent assay. The results were correlated with clinical data. Results. The median serum HE4 level in ovarian cancer patients was 98.7 (range, 80.3-222.8) pg/ml. Elevated serum HE4 levels before therapy significantly correlated with a poorer progression free survival (log-rank test, P = 0.017). Multivariate analysis revealed serum HE4 to be an independent prognostic factor for progression-free survival (P = 0.036). In multivariate regression analysis, high serum HE4 levels significantly correlated with high tumor grade and serous histology (P = 0.004 and 0.017). In addition, high serum HE4 levels were significantly associated with residual tumor size and operative time (P = 0.003 and 0.033). Conclusions. Pretreatment serum HE4 seems to be an additional factor for predicting the outcome of patients with epithelial ovarian cancer. Due to its independence from established prognostic factors, serum HE4 may provide additional prognostic information.

Original language	English
Pages (from-to)	1707-1712
Number of pages	6
Journal	Annals of surgical oncology
Volume	19
Issue number	5
DOIs	https://doi.org/10.1245/s10434-011-1943-5
Publication status	Published - 2012 May

Bibliographical note

Funding Information:
ACKNOWLEDGMENT This study was funded by the grant of the National Cancer Center, Korea (Grant No. 0910260-3). We thank Ms. Il Ji Jeon for her technical support.

All Science Journal Classification (ASJC) codes

Surgery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1245/s10434-011-1943-5

Cite this

@article{2a073a2c8cdc4b88af2049f877a53230,

title = "Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer",

abstract = "Background. This study was designed to determine whether serum HE4 is an independent prognostic factor in ovarian cancer patients. Methods. We measured HE4 in pretreatment serum samples from 80 women with epithelial ovarian cancer, using an enzyme-linked immunosorbent assay. The results were correlated with clinical data. Results. The median serum HE4 level in ovarian cancer patients was 98.7 (range, 80.3-222.8) pg/ml. Elevated serum HE4 levels before therapy significantly correlated with a poorer progression free survival (log-rank test, P = 0.017). Multivariate analysis revealed serum HE4 to be an independent prognostic factor for progression-free survival (P = 0.036). In multivariate regression analysis, high serum HE4 levels significantly correlated with high tumor grade and serous histology (P = 0.004 and 0.017). In addition, high serum HE4 levels were significantly associated with residual tumor size and operative time (P = 0.003 and 0.033). Conclusions. Pretreatment serum HE4 seems to be an additional factor for predicting the outcome of patients with epithelial ovarian cancer. Due to its independence from established prognostic factors, serum HE4 may provide additional prognostic information.",

author = "Kong, {Sun Young} and Han, {Mi Hwa} and Yoo, {Heon Jong} and Hwang, {Jong Ha} and Lim, {Myong Cheol} and Seo, {Sang Soo} and Yoo, {Chong Woo} and Kim, {Jae Hoon} and Park, {Sang Yoon} and Sokbom Kang",

note = "Funding Information: ACKNOWLEDGMENT This study was funded by the grant of the National Cancer Center, Korea (Grant No. 0910260-3). We thank Ms. Il Ji Jeon for her technical support.",

year = "2012",

month = may,

doi = "10.1245/s10434-011-1943-5",

language = "English",

volume = "19",

pages = "1707--1712",

journal = "Annals of surgical oncology",

issn = "1068-9265",

publisher = "Springer New York",

number = "5",

}

TY - JOUR

T1 - Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer

AU - Kong, Sun Young

AU - Han, Mi Hwa

AU - Yoo, Heon Jong

AU - Hwang, Jong Ha

AU - Lim, Myong Cheol

AU - Seo, Sang Soo

AU - Yoo, Chong Woo

AU - Kim, Jae Hoon

AU - Park, Sang Yoon

AU - Kang, Sokbom

N1 - Funding Information: ACKNOWLEDGMENT This study was funded by the grant of the National Cancer Center, Korea (Grant No. 0910260-3). We thank Ms. Il Ji Jeon for her technical support.

PY - 2012/5

Y1 - 2012/5

N2 - Background. This study was designed to determine whether serum HE4 is an independent prognostic factor in ovarian cancer patients. Methods. We measured HE4 in pretreatment serum samples from 80 women with epithelial ovarian cancer, using an enzyme-linked immunosorbent assay. The results were correlated with clinical data. Results. The median serum HE4 level in ovarian cancer patients was 98.7 (range, 80.3-222.8) pg/ml. Elevated serum HE4 levels before therapy significantly correlated with a poorer progression free survival (log-rank test, P = 0.017). Multivariate analysis revealed serum HE4 to be an independent prognostic factor for progression-free survival (P = 0.036). In multivariate regression analysis, high serum HE4 levels significantly correlated with high tumor grade and serous histology (P = 0.004 and 0.017). In addition, high serum HE4 levels were significantly associated with residual tumor size and operative time (P = 0.003 and 0.033). Conclusions. Pretreatment serum HE4 seems to be an additional factor for predicting the outcome of patients with epithelial ovarian cancer. Due to its independence from established prognostic factors, serum HE4 may provide additional prognostic information.

AB - Background. This study was designed to determine whether serum HE4 is an independent prognostic factor in ovarian cancer patients. Methods. We measured HE4 in pretreatment serum samples from 80 women with epithelial ovarian cancer, using an enzyme-linked immunosorbent assay. The results were correlated with clinical data. Results. The median serum HE4 level in ovarian cancer patients was 98.7 (range, 80.3-222.8) pg/ml. Elevated serum HE4 levels before therapy significantly correlated with a poorer progression free survival (log-rank test, P = 0.017). Multivariate analysis revealed serum HE4 to be an independent prognostic factor for progression-free survival (P = 0.036). In multivariate regression analysis, high serum HE4 levels significantly correlated with high tumor grade and serous histology (P = 0.004 and 0.017). In addition, high serum HE4 levels were significantly associated with residual tumor size and operative time (P = 0.003 and 0.033). Conclusions. Pretreatment serum HE4 seems to be an additional factor for predicting the outcome of patients with epithelial ovarian cancer. Due to its independence from established prognostic factors, serum HE4 may provide additional prognostic information.

UR - http://www.scopus.com/inward/record.url?scp=84862558119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862558119&partnerID=8YFLogxK

U2 - 10.1245/s10434-011-1943-5

DO - 10.1245/s10434-011-1943-5

M3 - Article

C2 - 21833668

AN - SCOPUS:84862558119

SN - 1068-9265

VL - 19

SP - 1707

EP - 1712

JO - Annals of surgical oncology

JF - Annals of surgical oncology

IS - 5

ER -

Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this